<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664648</url>
  </required_header>
  <id_info>
    <org_study_id>DV2-HBV-27</org_study_id>
    <nct_id>NCT03664648</nct_id>
  </id_info>
  <brief_title>DV2-HBV-27: Observational Pregnancy Registry</brief_title>
  <acronym>HBV-27</acronym>
  <official_title>HEPLISAV-B Pregnancy Registry: An Observational Study on the Safety of HEPLISAV-B Exposure in Pregnant Women and Their Offspring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to evaluate pregnancy outcomes among women who received a dose of
      HEPLISAV-B within 28 days prior to conception or at any time during pregnancy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Rate of Major Congenital Malformations in Live-Born Infants.</measure>
    <time_frame>Live-born infants will be followed to 12 months of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Still Births, Pre-Term, or Fetal Loss (Including Spontaneous Abortion) of any Gestational Age</measure>
    <time_frame>Follow-up will end at the time of pregnancy outcome up to 9 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pregnant</condition>
  <arm_group>
    <arm_group_label>Adult Pregnant Women Exposed to HEPLISAV-B</arm_group_label>
    <description>Adult women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HEPLISAV-B</intervention_name>
    <description>This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.</description>
    <arm_group_label>Adult Pregnant Women Exposed to HEPLISAV-B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women 18 years of age or older exposed to HEPLISAV-B within 28 days of conception or at any
        time during pregnancy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

          -  HEPLISAV-B exposure within 28 days prior to conception or at any time during pregnancy

        Exclusion Criteria:

          -  Less than 18 years of age

          -  HEPLISAV-B exposure greater than 28 days prior to conception
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant Women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deborah Covington, PhD</last_name>
    <phone>1-844-443-7734</phone>
    <email>heplisavbpregnancyregistry@ppdi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Randall Hyer, MD</last_name>
    <phone>(510) 848- 5100</phone>
    <email>rhyer@dynavax.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PPD Registry Office, Recruiting Nationwide</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnant</keyword>
  <keyword>Conceived</keyword>
  <keyword>HBV Vaccine</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Hepatitis B vaccine</keyword>
  <keyword>HBV</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Registry</keyword>
  <keyword>Prevention</keyword>
  <keyword>Female volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

